After exclusion of patients not suitable for stenting, the final study group comprised 217 patients.
We excluded 11 patients from our final study group, who had previously undergone placement of a HM XVE that failed.
For our final study group of 267 patients, the total follow-up time was 479.01 patient-years (median, 469 days).
We did a cross-sectional survey of 104 patients, then gave a questionnaire to the final study group of 716868%), a year or more later.
The final study group comprised 2010 cases and 2346 controls comprising 1211 household contacts and 1135 neighbours or community controls.
Data from one European man was excluded as he was subsequently discovered to have diabetes: the final study group therefore contained 20 South Asian and 19 European men.
These patients comprised the final study group.
The final study group consisted of 13868 patients (Table 1).
Thus, the final study group comprised 99 patients.
The final study group consisted of 85 patients (85 hips).
Thus the final study group consisted of 1094 patients.
